Cleland_nihr_cv_short

Short Curriculum Vitae for Professor John George Franklin Cleland

Nationality:

Degrees & Diplomas
M.B. Ch.B. with Commendation.
M.R.C.P. / F.R.C.P. (Glasgow and London)
Current Post:
Professor of Cardiology, University of Hull
Career History
a) Professor of Cardiology, University of Hull. 1999- b) Senior lecturer (BHF Funded), Clinical Research Initiative in Heart Failure, Glasgow. 1994-98. c) Senior Lecturer in Cardiology, Hammersmith Hospital, London. 1989 – 1994.
Relevant Current and Past Roles

a) Past chairman of the Working Group on Heart Failure of the ESC b) Founding Editor of the European Journal of Heart Failure (an official journal of the ESC) c) Member of the data standards committee on heart failure for the AHA/ACC Task Force d) Immediate past-chairman of the British Society for Heart Failure e) Steering Committee member for the UK NHS National Survey on Heart Failure
Professor John Cleland qualified in medicine at the University of Glasgow, Scotland in 1977. After
a period of postgraduate training and an introduction to research he was appointed first a Senior
Registrar and subsequently as Senior Lecturer in Cardiology and Honorary Consultant Cardiologist at
St Mary’s Hospital, Paddington and the Hammersmith Hospital, London from 1986-1994. In 1994
Professor Cleland was awarded a Senior Research Fellowship by the British Heart Foundation to
transfer to the Medical Research Council’s Clinical Research Initiative in Heart Failure. Professor
Cleland was appointed to the Foundation Chair of Cardiology at the University of Hull in 1999.
Professor Cleland’s main field of interest is in heart failure, extending from its epidemiology and
prevention, through the development and implementation of guidelines for the application of current
knowledge, to large randomised trials to study interventions for and disease areas in heart failure.
Particular current interests include the role of myocardial hibernation contributing to heart failure
and its treatment (including beta-blockers and revascularisation), diastolic heart failure in the
elderly, the potential deleterious effect of aspirin in heart failure, ventricular resynchronisation,
telemonitoring, implantable haemodynamic monitoring devices, atrial fibrillation in heart failure and
new interventions for acute decompensated heart failure. Active programmes for the assessment
of heart failure and its optimal management using cardiac impedance, magnetic resonance,
computer tomography and advanced electrophysiology are also in place.
Professor Cleland heads The Academic Unit of Cardiology that includes 3 Senior Lecturers and a
team of basic and clinical scientists, technicians and research nurses dedicated to the above
research programme.
Research Interests: 2008

My research interests are predominantly related to heart failure and its common aetiologies (myocardial scar and
hibernation), co-morbidities (atrial fibrillation, mitral regurgitation, pulmonary hypertension, renal dysfunction,
anaemia, diabetes and lung disease) and antecedents (hypertension and coronary disease).
I have led two large European surveys that enrolled over 20,000 patients with suspected heart failure and currently
run a large, detailed, longitudinal epidemiological programme that has enrolled more than 5,000 patients and
observed over 1,000 deaths. These surveys provide a wealth of information on diagnosis, risk stratification and met
and unmet needs of patients.
I chaired the Steering Committee of several landmark studies of heart failure including:-
CARE-HF: the definitive study showing improved morbidity and mortality with atrio-biventricular pacing
PEP-CHF: a study suggesting symptom and morbidity benefits of perindopril, an ACE inhibitor, in older patients
with heart failure but normal left ventricular ejection fraction. This study was also the first to define natriuretic
peptides as the best, simple marker for prognosis (an important aspect of diagnosis) for this particular condition.
TEN-HMS: a study suggesting that more intense monitoring of patients either using nurses or home telemonitoring
reduced mortality. Results subsequently supported by meta-analysis. Home telemonitoring may be the less
expensive service.
CHRISTMAS: a study showing that many patients with heart failure and ischaemic heart disease have viable
myocardium that fails to contract, which may be ‘resuscitated’ by treatment with beta-blockers. Indeed, myocardial
viability may be a major determinant of the response to beta-blockers.
HeartCycle: A large, ongoing study of TeleHealth sensors for heart failure and coronary artery disease funded by
the European Union FP7 programme.
I have served on the Steering Committee, DSMB and/or End-Points Committee of many more landmark studies of
acute or chronic heart failure including ATLAS, COMET, VERITAS, SURVIVE, REVERSE, CORONA, RED-HF.
Major current interests are the use of bio-markers and telemedicine to manage patients better, implanted device-
therapy for heart failure and investigation and treatment of disordered myocardial metabolism. My interest is to
explore these topics so that they can be developed into substantial, pragmatic trials that change clinical practice.

Selected Publications of original research or major reviews in journals with impact factor >9 since
2001
1. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L, for the
Cardiac Resynchronization – Heart Failure (CARE-HF) Study Investigators. The Effect of Cardiac
Resynchronization on Morbidity and Mortality in Heart Failure. NEJM. 2005; 352: 1539-49.
2. Cleland JG, Charlesworth A , Lubsen J , Swedberg K et al. A Comparison of the Effects of
Carvedilol and Metoprolol on 'Well-being', Morbidity and Mortality (The Patient-Journey) in
Patients with Heart Failure. JACC 2006; 47: 1603-1611
3. Cleland JG, Louis AA, Rigby AS, et al. Non-invasive home telemonitoring for patients with heart
failure at high risk of recurrent admission and death: the Trans-European Network-Home-Care
Management System (TEN-HMS) study. JACC. 2005;45:1654-64.
4. Radford MJ, Arnold JM, Bennett SJ, Cinquegrani MP, Cleland JG, et al. ACC/AHA key data
elements and definitions for measuring the clinical management and outcomes of patients with
chronic heart failure. Circulation. 2005;112:1888-916.
5. Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG. Carvedilol alone or in
combination with digoxin for atrial fibrillation in patients with heart failure? JACC 2003;42:1944-
51.
6. Cleland JGF, Pennell DJ, Ray SG, Coats AJ, MacFarlane PW, Murray GD, Dalle Mule J, Vered Z,
Lahiri A, on behalf of the CHRISTMAS investigators. Myocardial viability as a determinant of the
ejection fraction response to carvedilol in patients with heart failure. Lancet 2003; 362:14-21.
7. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Carvedilol Or Metoprolol European Trial
Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET). Lancet.
2003;362:7-13.
8. Cleland JG, Cohen-Solal A, Aguilar JC, et al. Management of heart failure in primary care (the
IMPROVEMENT of Heart Failure Programme): an international survey. Lancet. 2002;360:1631-9
9. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared
with dobutamine in severe low-output heart failure (the LIDO study). Lancet. 2002;360:196-
202
10. Cleland JG, Taylor J, Tendera M. Prognosis in heart failure with a normal ejection fraction.
NEJM 2007; 357:829-830.
11. Kjekshus, E. Apetrei, V. Barrios, M. Bohm, Cleland JG, and et al. Rosuvastatin in Older Patients
with Systolic Heart Failure. NEJM 357:ePub, 2007.
12. Mozaffarian D, Anker S, Anand I, Linker DT, Sullivan MD, Cleland JG, Carson PE, Maggioni AP,
Mann DL, Pitt B, Poole-Wilson PA, Levy WC. Prediction of Mode of Death in Heart Failure: the
Seattle Heart Failure Model. Circulation 2007; 116: 392-398.
13. Follath F, Cleland JG, Klein W, Murphy R. Etiology and response to drug treatment in heart
failure. JACC 32:1167-1172, 1998.
14. Cleland JG, Freemantle N, Ghio S, Fruhwald F, Shankar A, Marijianowski M, Verboven Y, Tavazzi
L. Predicting the Long-Term Effects of Cardiac Resynchronisation Therapy on Mortality from
Baseline Variables and the Early Response. JACC 2008.
15. Remme W, Torp-Pedersen C, Cleland JG, Poole-Wilson PA, Metra M, Komajda M, Swedberg K.,
Di Lenarda A, Spark P, Scherhag A, Moullet C, Lukas MA. Carvedilol protects better against
vascular events than Metoprolol in Heart Failure. Results from COMET. JACC 49:963-971, 2007.
16. McMurray JJV, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G, Krum H, Metra M,
O'Connor C, Parker JD, Torre Amione G, Van Veldhuisen D et al. and for the VERITAS
Investigators. Effects of Tezosentan or Symptoms and Clinical Outcomes in Patients with Acute
Heart Failure. The VERITAS Randomized Controlled Trials. JAMA 298:2009-2019, 2007.
17. Ingle L, Reddy P, Clark AL, Cleland JG. Diabetes lowers six-minute walk test performance in
heart failure. JACC 47:1909-1910, 2006.


Current Departmental Competitive Grants

British Heart Foundation
• Assessment of the risk associated with air travel in patients with chronic heart failure • Metformin Against Gliclazide in Patients with Diabetes and Heart-Failure European Union FP7
• HeartCycle (telehealth sensor programme for heart failure and coronary disease) Health Technology Assessment
• Does home oxygen therapy (HOT) in addition to standard care improve disease severity and symptoms in chronic heart failure? (Dr Andrew Clark – lead investigator)

Source: http://www.overcome.eu/Acute_Heart_Failure/profiles/Cleland/Cleland_NIHR_CV_Short.pdf